Surging. After the close of trading on the 30th, it was announced that "MDL-101", which is being developed for congenital muscular dystrophy type 1a (LAMA2-CMD), has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA), leading to buying activity. Orphan drug designation is a system aimed at promoting the development of new drugs for rare diseases with onset before the age of 18 in the United States and a patient population of less than 0.2 million. Upon obtaining manufacturing and marketing approval from the FDA for the designated development product, the right to receive priority review from the FDA for another development product can be obtained.